Q1 Net Income Declines, Lilly Collaboration Terminated, Debt Restructured

summarizeSummary

Rigel Pharmaceuticals reported a decline in Q1 net income and EPS despite revenue growth, announced the termination of its collaboration with Eli Lilly, and restructured its debt facility.

check_boxKey Events

• Q1 Financial Performance

  Reported Q1 2026 total revenues of $58.8 million (up 10.3% year-over-year) but net income decreased to $8.7 million (down 24.4% year-over-year) and diluted EPS fell to $0.44 from $0.63.

• Lilly Collaboration Terminated

  Eli Lilly provided notice to terminate the global exclusive license agreement for ocadusertib, effective June 15, 2026, eliminating future milestone and royalty payments from this program.

• Debt Restructuring

  Terminated a $60.0 million term loan facility and entered a new $40.0 million revolving credit facility with MidCap, drawing $8.0 million immediately. This alters the company's debt structure and liquidity profile.

• Product Sales Growth

  TAVALISSE sales increased 31% to $37.3 million, REZLIDHIA sales grew 31% to $8.0 million, and GAVRETO sales rose 7% to $9.6 million year-over-year.

auto_awesomeAnalysis

This quarterly report highlights mixed financial results with revenue growth offset by a significant drop in net income and EPS. The termination of the global exclusive license agreement with Eli Lilly for ocadusertib is a material negative event, eliminating future milestone and royalty payments from this program. Concurrently, the company restructured its debt, replacing a $60 million term loan with a $40 million revolving credit facility, which provides flexibility but reduces committed capital. New risk factors regarding potential tariffs on patented pharmaceutical products also introduce significant uncertainty. Investors should monitor the impact of the Lilly termination on future pipeline strategy and financial projections, as well as the company's ability to manage the new debt structure and navigate potential trade policy changes.